Form 4: Zivo Bioscience Director Laith Yaldoo Acquires Shares and Warrants in Recent Transaction

Director Laith Yaldoo reports acquisition of Zivo Bioscience shares and warrants through an entity.

Summary

• On October 16, 2024, Laith Yaldoo, a director of Zivo Bioscience, Inc., acquired 3,133 shares of common stock at a price of $15.957 per share.
• Following the transaction, Mr. Yaldoo beneficially owns 533,424 shares indirectly through an entity.
• Mr. Yaldoo also acquired a warrant to purchase 313 shares of common stock at an exercise price of $15.957, expiring on October 15, 2029.
• The warrant was also acquired indirectly through an entity.
• The transaction was reported on October 17, 2024.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity. The purchase of shares and warrants by a director could be seen as a positive signal, but without further context, it's difficult to gauge the overall impact.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the trading activities of company directors. It's common for directors to acquire shares, signaling confidence in the company's future prospects.

Stakeholder Impact

• The acquisition of shares by a director may be viewed positively by shareholders, potentially increasing investor confidence.

Key Dates

Keywords

Zivo Bioscience, Laith Yaldoo, Director, Share Acquisition, Warrant, Beneficial Ownership, Form 4